{"id":744052,"date":"2023-03-30T16:14:08","date_gmt":"2023-03-30T20:14:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/icosavax-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update\/"},"modified":"2023-03-30T16:14:08","modified_gmt":"2023-03-30T20:14:08","slug":"icosavax-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icosavax-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update\/","title":{"rendered":"Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n – FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate –<\/em>
\n \n <\/p>\n

\n – Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 –<\/em>\n <\/p>\n

\n – Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 –<\/em>\n <\/p>\n

\n – Cash and cash equivalents, restricted cash, and short-term investments of $219.4M at end 4Q 2022 –<\/em>\n <\/p>\n

SEATTLE, March 30, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX),<\/strong> a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.<\/p>\n

\u201cWe are proud of the progress we made in 2022, which included announcing positive interim results from our Phase 1\/1b IVX-121 monovalent respiratory syncytial virus trial, followed by promising durability data at the six-month timepoint. Additionally, we initiated our Phase 1 trial for IVX-A12, a bivalent respiratory syncytial virus and human metapneumovirus VLP vaccine candidate,\u201d said Adam Simpson, Chief Executive Officer of Icosavax. \u201cWe have now completed dosing and plan to announce topline data for this Phase 1 trial in 2Q 2023, followed by the planned initiation of a Phase 2 study in the second half of this year. In February, our IVX-A12 program was further boosted when it was granted Fast Track designation by the FDA. These achieved and prospective milestones, along with a 12-month durability data readout from our IVX-121 Phase 1b extension trial around mid-year, mean that 2023 is shaping up to be an exciting period for Icosavax as we continue to work towards our vision.\u201d<\/p>\n

\n Fourth Quarter 2022 and Subsequent Highlights <\/strong>\n <\/p>\n